F S&P 500
5,171.00 +16.25 (+0.32%) F Dow Jones
38,950.00 +118.00 (+0.30%) F Nasdaq
18,039.75 +39.00 (+0.22%) E-mini Russell 2000 Index Futur
2,062.70 +16.90 (+0.83%) Petróleo
78.86 +0.75 (+0.96%) Oro
2,330.00 +21.40 (+0.93%)
Almirall, S.A. (LBTSF)
Almirall, S.A.
Ronda General Mitre, 151
Barcelona 08022
Spain
34 93 291 30 00
https://www.almirall.com
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 1,904
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Carlos Gallardo Piqué | CEO, President, Member of Management Board & Chairman of the Board | 53.85k | N/D | 1972 |
| Mr. Michael McClellan | CFO & Member of Management Board | N/D | N/D | 1972 |
| Mr. Eloi Crespo Cervera | Chief Industrial Operations Officer & Member of Management Board | N/D | N/D | N/D |
| Mr. Esteve Conesa Panicot | Chief People & Culture Officer and Member of Management Board | N/D | N/D | N/D |
| Dr. Volker Koscielny | Chief Medical Officer & Member of Management Board | N/D | N/D | N/D |
| Dr. Karl Ziegelbauer | Chief Scientific Officer & Member of Management Board | N/D | N/D | N/D |
| Mr. Paolo Cionini | Chief Commercial Officer Europe & International and Member of Management Board | N/D | N/D | N/D |
| Ms. Isabel Cristina Gomes | Company Vice Secretary,Chief Legal Officer, General Counsel & Member of Management Board | N/D | N/D | N/D |
| Ms. Mercedes Diz Lopez | Chief Marketing Officer & Member of Management Board | N/D | N/D | N/D |
| Mr. Pablo Divasson del Fraile | Senior Director of Investor Relations | N/D | N/D | N/D |
Descripción
Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
Gestión corporativa
La calificación ISS Governance QuickScore de Almirall, S.A. a partir del 1 de mayo de 2024 es 2. Las puntuaciones principales son Auditoría: 4; Junta: 3; Derechos del accionista: 3; Compensación: 1.
